April 19, 2018 1:38 PM ET


Company Overview of Protea Biosciences Group, Inc

Company Overview

Protea Biosciences Group, Inc., a molecular information company, provides proprietary, bioanalytical workflows to the pharmaceutical and life science industries. It develops Histology Guided Mass Spec Imaging, a software suite that allows researchers to share, annotate, and direct the analysis of specific tissue morphologies and cell subpopulations by mass spec imaging; and prototype instrumentation of LAESI technology that integrates with laboratory instruments. The company also develops technology to improve the molecular characterization of biotherapeutics; and bioanalytical reagents and products to facilitate sample preparation prior to mass spectrometry analysis. In addition, it offers ...

1311 Pineview Drive

Suite 501

Morgantown, WV 26505

United States

Founded in 2001

25 Employees





Key Executives for Protea Biosciences Group, Inc

VP of Research & Development and Chief Scientific Officer
Age: 42
Total Annual Compensation: $180.0K
Age: 71
Total Annual Compensation: $240.0K
Age: 48
Compensation as of Fiscal Year 2016.

Protea Biosciences Group, Inc Key Developments

Motion for Asset Sale Approved for Protea Biosciences, Inc.

The US Bankruptcy Court gave an order approving the sale of substantially all the assets of Protea Biosciences, Inc. on January 26, 2018. The debtor has been authorized to sell substantially all its assets to Summit Resource Inc., the stalking horse bidder for a purchase price of $1.3 million in cash. The debtor did not receive any other competing bids for the purchase of its assets and therefore Summit Resource Inc. emerged as the winning bidder.

Final DIP Financing Approved for Protea Biosciences, Inc.

The US Bankruptcy Court gave an order to Protea Biosciences, Inc. to obtain DIP financing on a final basis on January 19, 2018. As per the order, the debtor has been authorized to obtain a term loan in the amount of $1.38 million from Summit Resource Inc. The DIP loan would either carry an interest rate of 15% p.a., along with an additional 5% p.a. interest in the event of default. The DIP facility would mature either on January 31, 2018 or the date of consummation of the sale of substantially all assets, whichever is earlier. Adequate protection would be provided to the DIP lenders in the form of super-priority administrative expense claims which is subject to a carve-out towards unpaid professional fees / administrative expenses and first priority lien upon and security interest in the debtor’s collateral. The Court had granted the debtor an interim approval to access $0.48 million as DIP financing on December 12, 2017.

Bidding Procedure Approved for Protea Biosciences, Inc.

The US Bankruptcy Court gave an order approving the bidding procedures relating to the sale of substantially all assets of Protea Biosciences, Inc. on December 13, 2017. The Court approved the asset purchase agreement between the debtor and Summit Resource Inc., the stalking horse bidder, for the sale of its substantially all its assets for a purchase price of $1 million in the form of credit bid. To qualify as a qualified bidder, interested parties should submit their bids at least seven business days prior to sale hearing date along with an earnest money deposit of $0.20 million. The initial minimum overbid should be at least in the amount of $1.50 million. At the auction, the subsequent bids would be in increments of $0.05 million. The stalking horse bidder would be entitled to a break-up fee of $0.1 million. The sale hearing is scheduled for January 24, 2018.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3Bar Biologics Inc. United States

Recent Private Companies Transactions

December 5, 2017
All Assets of Protea Biosciences Group, Inc

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
Tax Management Inc United States
John F. Kennedy Center For The Performing Arts United States
NYC2012, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Protea Biosciences Group, Inc, please visit www.proteabio.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.